Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04949308
Other study ID # JR_nNO_PCD_09_2020
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date December 31, 2022

Study information

Verified date June 2021
Source University Hospital Muenster
Contact Johanna Raidt, MD
Phone +49 251 83 40003
Email Johanna.Raidt@ukmuenster.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder characterized by dysfunction of motile cilia associated with recurrent infections of the airways, laterality defects (Situs inversus totalis in about 50% of cases) and fertility problems. At present, mutations in > 45 genes associated with PCD and mucociliary clearance disorders have been identified, representing most likely two thirds of all human cases. The aims of this study are: 1. Correlation between nasal NO levels and distinct PCD genotypes 2. Determination of further parameters potentially associated with nasal NO levels in genotyped PCD individuals 1. course of clinical manifestations (e.g. neonatal distress, infections, bronchiectasis) 2. diagnostic results (HVMA, TEM, IF) 3. lung function outcome (FVC, FEV1)


Description:

Nasal Nitric Oxide (nNO) concentration is usually low or very low in patients with Primary Ciliary Dyskinesia (PCD) for yet unknown reasons (1). Measured nNO holds a strong ability to separate healthy subjects from patients with PCD in both childhood and adulthood and across several different nNO sampling modalities (2) (3-5) and nNO is widely used as an important supplementary diagnostic test for PCD work up in both Europe (6) and North America (7). Low nNO in PCD was first reported 26 years ago (8). Nasal NO has been associated with host paranasal sinus defense as sufficient nNO production in non-PCD subjects is thought to play a role in maintaining paranasal sinus sterility (9). Furhermore, ciliary beating seems to be upregulated by a NO dependent pathway in bovine airway epithelium (10), influencing mucociliary clearance. However, human in vitro studies of ciliated airway cells in air-liquid-interface (ALI) culture have been ambiguous as to whether the biosynthesis of NO in PCD is impaired (11) (12) or not (13; 14) and the etiology of low nNO in PCD and presumed link to ciliary beating remains unclear. So far, attempts to link PCD phenotype and genotype has indicated that patients with PCD harboring CCDC39 and CCDC40 mutations may have a poorer lung function development (15). In rare cases of PCD (<5%) (16) nNO concentration is within normal range. More than 14 different PCD-causing genes (e.g RSPH1, GAS8, RPGR, CCNO, CCDC103, CFAP221, DNAH9, FOXJ1, GAS2L2, LRRC56, NEK10, SPEF2, STK36, TTC12) has been associated with nNO values above the agreed cut off for nNO-production rate of 77 nL/min in a few patients with PCD (16). However, individuals with NEK10 or FOXJ1 mutations, for example, display a very severe respiratory phenotype (17), but making a diagnosis is challenging because of normal nNO values as well as apparently normal ciliary beating. Since nNO also holds potential as an outcome parameter in future clinical trials of PCD, better understanding of nNO in PCD is warranted. Demand of large number of patients with PCD is crucial, keeping the rareness of nearnormal and normal nNO levels in PCD in mind. Motivated by the analysis of lung function in a large cohort of genotyped PCD-patients, this multicenter Involvement across international PCD centers is an obvious opportunity for gaining such further knowledge with the focus on nasal NO. The aims of this study are: 1. Correlation between nasal NO levels and distinct PCD genotypes 2. Determination of further parameters potentially associated with nasal NO levels in genotyped PCD individuals 1. course of clinical manifestations (e.g. neonatal distress, infections, bronchiectasis) 2. diagnostic results (HVMA, TEM, IF) 3. lung function outcome (FVC, FEV1) Inclusion criteria: 1. Patients with a genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD 2. PCD individuals of all age groups with at least one nNO measurement performed according to diagnostic guidelines. Serial nNO measurements should be included if available (e.g. yearly), at least for infants and young children


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date December 31, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Patients with a genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD 2. PCD individuals of all age groups with at least one nNO measurement performed according to diagnostic guidelines. Serial nNO measurements should be included if available (e.g. yearly), at least for infants and young children Exclusion Criteria: -

Study Design


Locations

Country Name City State
Germany University Hospital Münster Münster NRW

Sponsors (37)

Lead Sponsor Collaborator
University Hospital Muenster Abderrahmane Mami Hospital, Bambino Gesù Hospital and Research Institute, Charite University, Berlin, Germany, Federico II University, Göteborg University, Hacettepe University, Hadassah Medical Organization, Hannover Medical School, Hospital de Niños R. Gutierrez de Buenos Aires, Hospital Vall d'Hebron, KU Leuven, Marmara University, Medical University of Vienna, NOVA Medical School, Oslo University Hospital, Rigshospitalet, Denmark, Royal Brompton & Harefield NHS Foundation Trust, Ruhr University of Bochum, Schneider Children's Medical Center, Israel, The Leeds Teaching Hospitals NHS Trust, University Children's Hospital, Zurich, University College, London, University Hospital of Cologne, University Hospital, Martin, University Hospital, Motol, University of Belgrade, University of Bern, University of Dundee, University of Geneva, Switzerland, University of Leicester, University of Nicosia, University of Pisa, University of Sao Paulo, University of Southampton, University of Valencia, VU University Medical Center

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Genotype-nasal Nitric Oxide Corelation nNO in correlation to the genetic make-up up to 20 years retrospective
See also
  Status Clinical Trial Phase
Recruiting NCT05889013 - Utility of PCD Diagnostics to Improve Clinical Care
Recruiting NCT01246258 - Otolith Function in Patients With Primary Ciliary Dyskinesia N/A
Completed NCT04858191 - Utilizing Hyperpolarized 129Xe Magnetic Resonance Imaging in Children With Primary Ciliary Dyskinesia
Completed NCT05712798 - Physiological Responses to Exercise Tests in Primary Ciliary Dyskinesia Compared With Healthy Individuals
Completed NCT03370029 - Respiratory Muscle Strength, Exercise Capacity and Physical Activity Levels in Children Primary Ciliary Dyskinesia
Completed NCT00368446 - Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease
Recruiting NCT05374720 - Analysis of the Molecular Composition of Tubal Cilia in Patients With or Without Ectopic Pregnancy N/A
Completed NCT05816876 - Muscle Function, Exercise Capacity and Physical Activity Level in Primary Ciliary Dyskinesia and Kartagener Syndrome
Recruiting NCT04717115 - Genotype/Phenotype Correlation With Focus on Lung Function in Primary Ciliary Dyskinesia (PCD)
Recruiting NCT03279965 - MRI in Cystic Fibrosis and Primary Ciliary Dyskinesia N/A
Recruiting NCT03320382 - Multiple Breath Washout, a Clinimetric Dataset
Recruiting NCT04602481 - COVID-19 in People With Primary Ciliary Dyskinesia
Not yet recruiting NCT02704455 - Registry Study on Primary Ciliary Dyskinesia in Chinese Children N/A
Completed NCT00323167 - Rare Genetic Disorders of the Breathing Airways
Recruiting NCT05932316 - Evaluating Bronchodilator Response in Patients With Bronchiectasis N/A
Completed NCT03832491 - Effect of Game Based Approach on Oxygenation, Functional Capacity and Quality of Life in Primary Ciliary Dyskinesia N/A
Recruiting NCT05951478 - DCP (RaDiCo Cohort) (RaDiCo-DCP)
Completed NCT06028607 - Feasibility of Consumption of Nutritional Supplementation in Primary Ciliary Dyskinesia N/A
Recruiting NCT05685186 - A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults
Recruiting NCT05161858 - Longitudinal Characterization of Respiratory Tract Exacerbations and Treatment Responses in Primary Ciliary Dyskinesia